ABOUT US
Northern Development was founded in 2014 with the objective of developing the next generation of heart-assist device.
It has one of the most experienced development teams in the market with more than 100 years accumulated experience in the development and use of VADs.
Northern Development has Head office in Oslo, Norway.
In 2016, Northern Research were established as part of the Northern Group, designing the PulseVAD components. Northern Research is located in Sydney, Australia, where we have office and research facilities.
Northern Research is headed by John Begg, Chief Technical Officer.
Partners for our program are Norwegian Research Counsil, Innovation Norway, Oslo University Hospital, University of New South Wales and MTPConnect*.
*Delivered by MTPConnect, the Australian Government's $45 million BioMedTech Horizons program, is a Medical Research Future Fund (MRFF) initiative to support innovative collaborative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key health challenges as well as maximise entrepreneurship and idea potential
TECHNOLOGY
PulseVad is the first generation Smart pump coming to the market.
PulseVad provides adaptive and pulsatile flow, syncronized to the heart, using new sensor technology. The pump has adaptive flow according to patient physiological need.
The pulsed flow and pump design reduce the risk of thrombus formation and risk of celebral emboli.
PulseVad will be implanted minimally invasive and off pump, with a special designed system for access and placement.
Smart pump
Syncronized flow – Minimal Invasive implant – Adaptive to patients needs – Route LA to DA – Thrombus minimalization
MARKET
Total market potential for long-term assist devices is estimated to be
approx 160.000 pcs, with a 50/50 split between patients with preserved and reduced EF.
Currently no medical treatment is offered to patients with preserved EF, and where PulseVad will offer a break through technology when introduced in the market.
PulseVad will also offer treatment options for the traditional VAD patient with reduced EF.
